Literature DB >> 10446447

The role of immunosuppression and immune-activation in classic Kaposi's sarcoma.

G Touloumi1, A Hatzakis, I Potouridou, I Milona, J Strarigos, A Katsambas, G Giraldo, E Beth-Giraldo, R J Biggar, N Mueller, D Trichopoulos.   

Abstract

Immunodeficiency and elevated levels of cytokines have been associated with the development of Kaposi's sarcoma (KS) lesions in patients with AIDS and iatrogenic immunodeficiency. However, their role in classic KS (CKS) is unclear. We measured peripheral blood cell levels, including T-cell subsets, as well as neopterin and beta(2)-microglobulin in 91 HIV-negative Greek patients with histologically confirmed CKS and in 107 controls matched for age and sex. CKS cases had slightly lower leukocyte counts (p = 0.08) and lymphocyte counts (p = 0.02). Although the percentage of CD4 and CD8 T-lymphocytes were not significantly different from controls (p = 0.10 and p = 0.45, respectively), CD4 T-lymphocytes were lower in cases than controls (812 cells/microliter and 1,009 cells/microliter, respectively; p = 0.01); part of this difference resulted from the lower lymphocyte counts (p = 0.07 after adjusting for lymphocyte counts). However, neopterin and beta(2)-microglobulin were both considerably elevated [geometric mean (95% CI): 8.35 (7.27-9.73) nmol/L and 2,904 (2,479-3,401) microgram/L in cases and 5.86 (5.40-6. 35) nmol/L and 2,042 (1,880-2,218) microgram/L in controls, respectively]. We conclude that CKS patients are predominantly characterised by immune activation, although an element of minor immunosupression may also be present. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446447     DOI: 10.1002/(sici)1097-0215(19990909)82:6<817::aid-ijc8>3.0.co;2-7

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  A multiplex panel of plasma markers of immunity and inflammation in classical kaposi sarcoma.

Authors:  Peter V Aka; Troy J Kemp; Charles S Rabkin; Meredith S Shiels; Mark N Polizzotto; Carmela Lauria; Francesco Vitale; Ligia A Pinto; James J Goedert
Journal:  J Infect Dis       Date:  2014-08-22       Impact factor: 5.226

2.  Kaposi's Sarcoma-Associated Herpesvirus Infection of Neurons in HIV-Positive Patients.

Authors:  For Yue Tso; Ashley Sawyer; Eun Hee Kwon; Victor Mudenda; Dianne Langford; You Zhou; John West; Charles Wood
Journal:  J Infect Dis       Date:  2017-06-15       Impact factor: 5.226

Review 3.  Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis.

Authors:  Lyubomir A Dourmishev; Assen L Dourmishev; Diana Palmeri; Robert A Schwartz; David M Lukac
Journal:  Microbiol Mol Biol Rev       Date:  2003-06       Impact factor: 11.056

Review 4.  Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma.

Authors:  Giovanni Barillari; Barbara Ensoli
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

5.  Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada.

Authors:  Robert Dubrow; Li Qin; Haiqun Lin; Raúl U Hernández-Ramírez; Romain S Neugebauer; Wendy Leyden; Keri N Althoff; Chad J Achenbach; Nancy A Hessol; Sharada P Modur; Gypsyamber DʼSouza; Ronald J Bosch; Surbhi Grover; Michael A Horberg; Mari M Kitahata; Angel M Mayor; Richard M Novak; Charles S Rabkin; Timothy R Sterling; James J Goedert; Amy C Justice; Eric A Engels; Richard D Moore; Michael J Silverberg
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-01       Impact factor: 3.731

6.  Risk of classical Kaposi sarcoma by plasma levels of Epstein-Barr virus antibodies, sCD26, sCD23 and sCD30.

Authors:  Colleen Pelser; Jaap Middeldorp; Sam M Mbulaiteye; Carmela Lauria; Angelo Messina; Enza Viviano; Nino Romano; Francesco Vitale; James J Goedert
Journal:  Infect Agent Cancer       Date:  2010-10-12       Impact factor: 2.965

7.  Risk factors for classical Kaposi sarcoma in a population-based case-control study in Sicily.

Authors:  Lesley A Anderson; Carmela Lauria; Nino Romano; Elizabeth E Brown; Denise Whitby; Barry I Graubard; Yan Li; Angelo Messina; Lorenzo Gafà; Francesco Vitale; James J Goedert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

8.  Delayed-type hypersensitivity in classic Kaposi sarcoma patients and controls.

Authors:  R M Valenti; E Amodio; J-M Nam; L Preiss; B I Graubard; N Romano; J J Goedert
Journal:  Br J Cancer       Date:  2011-01-18       Impact factor: 7.640

9.  Severely Disseminated Kaposi Sarcoma after ABO-Incompatible Kidney Transplantation Treated Successfully with Paclitaxel and Gemcitabine Combined with Hemodialysis.

Authors:  Tobias Bomholt; Anders Krarup-Hansen; Martin Egfjord; Søren Schwartz Sørensen; Niels Junker
Journal:  Case Rep Transplant       Date:  2019-12-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.